Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
NCT ID: NCT00388076
Last Updated: 2017-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
86 participants
INTERVENTIONAL
2006-04-28
2009-07-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1
pazopanib and paclitaxel
Pazopanib
pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
paclitaxel
in combination with pazopanib
Part 2
pazopanib, paclitaxel, and carboplatin
Pazopanib
pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
paclitaxel
in combination with pazopanib
carboplatin
in combination with pazopanib
Part 3
pazopanib, paclitaxel, and lapatinib
Pazopanib
pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
Lapatinib
Lapatinib in combination with pazopanib and paclitaxel in Part 3
paclitaxel
in combination with pazopanib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pazopanib
pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
Lapatinib
Lapatinib in combination with pazopanib and paclitaxel in Part 3
paclitaxel
in combination with pazopanib
carboplatin
in combination with pazopanib
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group performance Status of 0 or 1
* Peripheral neuropathy of Grade 1 or less
* Adequate bone marrow function (absolute neutrophils, platelets and hemoglobin levels as per protocol)
* Adequate renal function as per protocol
* Urine creatinine ratio as per protocol
* Adequate hepatic function as per protocol
* Coagulation tests as per protocol
* Male of female at least 18 years of age
* A woman is eligible to enter and participate in the study if she is of:
* Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any woman who:
* Has had a hysterectomy,
* Has had a bilateral oophorectomy (ovariectomy),
* Has had a bilateral tubal ligation,
* Is post-menopausal (total cessation of menses for at least 1 year)
* Childbearing potential, has a negative serum or urine pregnancy test at screening, and agrees to one of the following:
* An intrauterine device (IUD) with a documented failure rate of less than 1% per year.
* Vasectomized partner who is sterile prior to the patient's entry and is the sole sexual partner for that woman.
* Complete abstinence from sexual intercourse for 14 days before exposure to investigation product, throughout the clinical trial, and for at least 21 days after the last dose of investigational product.
* Double-barrier contraception defined as condom with spermicidal jelly, foam, suppository, or film; OR male condom and diaphragm.
* Predicted life expectancy of at least 12 weeks
* Written informed consent
* Able to swallow and retain oral medications.
Exclusion Criteria
* No major surgery, nor cytotoxic chemotherapy, investigational agents, or radiotherapy within the last 28 days and subject must have recovered fully from whatever their last treatment was at the time of enrollment.
* Women who are pregnant or breast feeding are not eligible to enroll.
* Cannot have poorly controlled hypertension.
* Cannot have corrected QT (QTc) prolongation
* Cannot have Class III or IV heart failure as defined by the New York Heart Association functional classification system.
* Cannot have arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within the last 3 months.
* Cannot use of therapeutic warfarin.
* Cannot have history of bleeding (hemoptysis, hematuria, GI blood loss, epistaxis, or others with greater than Grade 1 according to CTC Criteria) within six weeks prior to beginning therapy or any clinical indications of current active bleeding or bleeding diathesis.
* Cannot have history or clinical evidence of CNS metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 2 months prior to beginning study treatment.
* Cannot have any serious and/or unstable pre-existing medical, psychiatric, or other condition (including laboratory abnormalities) that could interfere with patient safety or obtaining consent.
* Cannot have history of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel that could affect absorption, distribution, metabolism or excretion of pazopanib, paclitaxel, or carboplatin. Has any unresolved bowel obstruction or diarrhea. Has clinically significant gastrointestinal abnormalities that may increase the risk for GI bleeding including, but not limited to:
* active peptic ulcer disease,
* known intraluminal metastatic lesion(s) with suspected bleeding,
* inflammatory bowel disease including ulcerative colitis, or other GI conditions with increased risk of perforation,
* history of abdominal fistula, GI perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment.
* Subject must not have psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
* Subject must not take any specifically prohibited medication specified in the protocol during the study or requires any of these medications during treatment with pazopanib.
* Subject must not have clinical history, current alcohol or illicit drug use which, in the judgment of the Investigator, would interfere with the patient's ability to comply with the dosing schedule and protocol-specified evaluations.
* Subject must not be allergic to either TAXOL or PARAPLATIN, or any other taxane or platinum containing compound.
* Subject must not have a current diagnosis of cervical cancer.
* Subject must not have known endobronchial metastasis or involvement of large pulmonary vessel(s) by tumor.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
New Brunswick, New Jersey, United States
GSK Investigational Site
Cleveland, Ohio, United States
GSK Investigational Site
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Burris HA 3rd, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, Levinson KT, Lindquist D, Gainer SD, Dar MM, Suttle AB, Ball HA, Tan AR. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther. 2012 Aug;11(8):1820-8. doi: 10.1158/1535-7163.MCT-11-0997. Epub 2012 Jun 7.
Tan AR, Dowlati A, Jones SF, Infante JR, Nishioka J, Fang L, Hodge JP, Gainer SD, Arumugham T, Suttle AB, Dar MM, Lager JJ, Burris HA 3rd. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist. 2010;15(12):1253-61. doi: 10.1634/theoncologist.2010-0095. Epub 2010 Dec 8.
Tan AR, Dowlati A, Stein MN, Jones SF, Infante JR, Bendell J, Kane MP, Levinson KT, Suttle AB, Burris HA 3rd. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. Br J Cancer. 2014 May 27;110(11):2647-54. doi: 10.1038/bjc.2014.233. Epub 2014 May 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VEG105427
Identifier Type: -
Identifier Source: org_study_id